Navigation Links
MiMedx Group, Inc. Receives CE Certification for Its CollaFix™ Surgical Mesh CD
Date:1/10/2012

KENNESAW, Ga., Jan. 10, 2012 /PRNewswire/ -- MiMedx Group, Inc. (OTCBB: MDXG), an integrated developer, manufacturer and marketer of patent protected regenerative biomaterials and bioimplants processed from human amniotic membrane, announced today that it has received the certification for the Company's proprietary CollaFix™ Surgical Mesh CD.  This certification of CollaFix™ Surgical Mesh CD, which is a Class III product in Europe, was issued by the Company's notified body, AMTAC Certification Services, Limited, based in the United Kingdom.

This certification is the first for the Company's CollaFix™ platform technology.

Parker H. "Pete" Petit, Chairman and CEO commented, "We are very pleased to receive our first regulatory certification for our unique CollaFix™ technology.  Our collagen fibers, that are the size of human hair, are fabricated in continuous lengths and have similar strength and stiffness to human tendons.  The fibers are bio-compatible and resorbable.  We expect this certification to be the first of many in a line of products using our CollaFix™ technologies to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair."

CollaFix™ Surgical Mesh CD has not been cleared for use in the United States.

About the Company

MiMedx® is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and bioimplants processed from human amniotic membrane. "Innovations in Regenerative Biomaterials" is the framework behind our mission to give physicians products and tissues to help the body heal itself. Our biomaterial platform technologies include the device technologies HydroFix® and CollaFix®, and our tissue technologies, AmnioFix® and EpiFix®. Our tissue technologies, processed from the human amniotic membrane, utilize our proprietary Purion® process that was developed by our wholly-owned subsidiary, Surgical Biologics, to produce a safe, effective and minimally manipulated implant. Surgical Biologics is the leading supplier of amniotic tissue, having supplied over 60,000 implants to date to distributors and OEMs for application in the Ophthalmic, Orthopedics, Spine, Wound Care and Dental sectors of healthcare.

Safe Harbor Statement

This press release includes statements that look forward in time or that express management's beliefs, expectations or hopes.  Such statements are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995.  These statements include, but are not limited to, the potential for future clearances of the Company's other product submissions and the outcomes achieved from the use of the Company's products. These statements are based on current information and belief, and are not guarantees of future performance.  Among the risks and uncertainties that could cause actual results to differ materially from those indicated by such forward-looking statements include that the failure to receive certifications or the pace of such certifications of future products from the Company's other submissions, the inability of the products to achieve desired outcomes and the risk factors detailed from time to time in the Company's periodic Securities and Exchange Commission filings, including, without limitation, its 10-K filing for the fiscal year ended December 31, 2010 and its most recent Form 10-Q. By making these forward-looking statements, the Company does not undertake to update them in any manner except as may be required by the Company's disclosure obligations in filings it makes with the Securities and Exchange Commission under the federal securities laws.

 

 


'/>"/>
SOURCE MiMedx Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. MiMedx Group Announces Temporary Trading Symbol Designation
2. MiMedx Group, Inc. to Present at Noble Financial Sixth Annual Equity Conference
3. MiMedx Group, Inc. Announces Release Date For Third Quarter Results
4. MiMedx Group, Inc. to Present at the 13th Annual Needham Growth Conference
5. MiMedx to Attend American Academy of Orthopedic Surgeons Annual Meeting
6. MiMedx Announces Launch of AmnioFix™
7. MiMedx Group, Inc. to Present at the 10th Annual Needham Healthcare Conference
8. MiMedx Group Announces 2010 Results
9. MiMedx Group Announces First Quarter 2011 Results
10. MiMedx Group, Inc. to Present at the Noble Financial Capital Markets Seventh Annual Equity Conference
11. MiMedx Group Completes $5,000,000 Private Placement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 01, 2016 , ... ... for North American hospitals, will present its chain-of-custody solution for tracking and securing ... Las Vegas, Nev., Dec. 4-8, 2016. , Aerocom has a proven solution for ...
(Date:12/2/2016)... ... December 02, 2016 , ... ... consortium of pharmaceutical and biotechnology companies dedicated to collaboratively developing improved chemistry, ... in supplying a vendor-supported, portable online UHPLC, with robust, probe-based sampling. ...
(Date:11/30/2016)... ... November 30, 2016 , ... ... Voice Coil Actuator with a flexure design that ensures high alignment accuracy by ... pricing and is ideally suited where extreme precision is required, such as in ...
(Date:11/30/2016)... SEATTLE , Nov. 30, 2016  The ... Allen Cell Collection: the first publicly available collection ... stem cells that target key cellular structures with ... Medical Research, these powerful tools are a crucial ... cells to better understand what makes human cells ...
Breaking Biology Technology:
(Date:12/2/2016)... , Dec. 1, 2016   SoftServe , ... BioLock , an electrocardiogram (ECG) biosensor analysis ... a key IoT asset. The smart system ensures ... vehicle,s steering wheel and mobile devices to easily ... As vehicle technology advances, so too ...
(Date:11/29/2016)... 29, 2016 BioDirection, a privately held medical ... the objective detection of concussion and other traumatic brain ... completed a meeting with the U.S. Food and Drug ... Pre-Submission Package. During the meeting company representatives reviewed plans ... precursor to commencement of a planned pilot trial. ...
(Date:11/28/2016)... 28, 2016 "The biometric ... 16.79%" The biometric system market is in the ... the near future. The biometric system market is expected ... at a CAGR of 16.79% between 2016 and 2022. ... biometric technology in smartphones, rising use of biometric technology ...
Breaking Biology News(10 mins):